Skip to search formSkip to main contentSkip to account menu

CVX-060

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Parallel synthesis and screening of peptide conjugates.
Peptide conjugates represent an emerging class of therapeutics. However, in contrast to that of small molecules and peptides, the… 
2013
2013
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC…
2533 Background: PF-04856884 is a recombinant humanized monoclonal antibody fused to two Ang-2 binding peptides. Axitinib is a… 
2012
2012
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib.
3032 Background: CVX-060 (CVX) is a humanized monoclonal antibody fused to two Ang2 binding peptides. The recommended phase 2… 
2012
2012
Abstract 1386: Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models
The clinical efficacy of anti-angiogenic therapies has been difficult to predict, and in this era of personalized medicine… 
2010
2010
First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.
2524 Background: CVX-060 is a recombinant humanized monoclonal antibody fused to two angiopoietin-2 (Ang2) binding peptides. In… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)